Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Paesmans

Showing results (151-160 of 187) with videos related to

Pageof 19
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2009
A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignanciesM Moreau, J Klastersky, A Schwarzbold, et al.
British Journal of Cancer|May 20, 2004
CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patientsJ-L Pujol, O Molinier, W Ebert, et al.
Lung Cancer (Amsterdam, Netherlands)|January 8, 2004
Consensus: the follow-up of the treated patientM Saunders, J P Sculier, D Ball, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2002
A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancerJ P Sculier, J J Lafitte, J Lecomte, et al.
Bone|September 2, 2020
Discriminating value of HR-pQCT for fractures in women with similar FRAX scores: A substudy of the FRISBEE cohortS I Cappelle, M Moreau, R Karmali, et al.
Bone Marrow Transplantation|January 12, 2010
Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer studyR Herbrecht, J Maertens, L Baila, et al.
The Journal of Antimicrobial Chemotherapy|October 21, 2009
An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patientsC Viscoli, R Herbrecht, H Akan, et al.
Revue Des Maladies Respiratoires|March 13, 1998
[Prognostic factors in advanced stage non-small cell bronchial cancer: experiences of the European Lung Cancer Working Party]J P Sculier, M Paesmans, P Libert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working PartyJ P Sculier, M Paesmans, J Thiriaux, et al.
British Journal of Cancer|October 12, 2000
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancerJ P Sculier, J J Lafitte, M Paesmans, et al.
Pageof 19

Showing results (151-160 of 187) with videos related to

Sort By:
Pageof 19
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2009
A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignanciesM Moreau, J Klastersky, A Schwarzbold, et al.
British Journal of Cancer|May 20, 2004
CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patientsJ-L Pujol, O Molinier, W Ebert, et al.
Lung Cancer (Amsterdam, Netherlands)|January 8, 2004
Consensus: the follow-up of the treated patientM Saunders, J P Sculier, D Ball, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2002
A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancerJ P Sculier, J J Lafitte, J Lecomte, et al.
Bone|September 2, 2020
Discriminating value of HR-pQCT for fractures in women with similar FRAX scores: A substudy of the FRISBEE cohortS I Cappelle, M Moreau, R Karmali, et al.
Bone Marrow Transplantation|January 12, 2010
Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer studyR Herbrecht, J Maertens, L Baila, et al.
The Journal of Antimicrobial Chemotherapy|October 21, 2009
An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patientsC Viscoli, R Herbrecht, H Akan, et al.
Revue Des Maladies Respiratoires|March 13, 1998
[Prognostic factors in advanced stage non-small cell bronchial cancer: experiences of the European Lung Cancer Working Party]J P Sculier, M Paesmans, P Libert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working PartyJ P Sculier, M Paesmans, J Thiriaux, et al.
British Journal of Cancer|October 12, 2000
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancerJ P Sculier, J J Lafitte, M Paesmans, et al.
Pageof 19